Sectors & IndustriesHealthcareDrug Manufacturers - Specialty & Generic
Best Pharmaceutical Stocks to Buy Now (2025)
Top pharmaceutical stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best pharmaceutical stocks to buy now. Learn More.

Industry: Drug Manufacturers - Spec...
B
Pharmaceutical is Zen Rated B and is the 38th ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Market Cap
Dividend Yield
Payout Ratio
Last Dividend
Annual Dividend
Dividend Percentile
Dividend Dropped Count (L10Y)
Ex-dividend Date
Div. Payment Date
PCRX
PACIRA BIOSCIENCES INC
$1.13BN/A0.00%N/AN/AN/AN/A
HCM
HUTCHMED (CHINA) LTD
$2.40BN/A0.00%N/AN/AN/AN/A
SUPN
SUPERNUS PHARMACEUTICALS INC
$1.71BN/A0.00%N/AN/AN/AN/A
ORGO
ORGANOGENESIS HOLDINGS INC
$539.02MN/A0.00%N/AN/AN/AN/A
COLL
COLLEGIUM PHARMACEUTICAL INC
$850.74MN/A0.00%N/AN/AN/AN/A
AMRX
AMNEAL PHARMACEUTICALS INC
$2.23BN/A0.00%N/AN/AN/AN/A
KMDA
KAMADA LTD
$365.16M3.15%0.00%$0.2000$0.2061%0
PAHC
PHIBRO ANIMAL HEALTH CORP
$681.68M2.85%100.00%$0.1200$0.4856%0
ALKS
ALKERMES PLC
$4.42BN/A0.00%$1.0700N/AN/A0
PRGO
PERRIGO CO PLC
$3.43B3.35%-88.60%$0.2900$0.8463%0
DVAX
DYNAVAX TECHNOLOGIES CORP
$1.32BN/A0.00%N/AN/AN/AN/A
CPIX
CUMBERLAND PHARMACEUTICALS INC
$63.28MN/A0.00%N/AN/AN/AN/A
ANIP
ANI PHARMACEUTICALS INC
$1.51BN/A0.00%N/AN/AN/AN/A
IRWD
IRONWOOD PHARMACEUTICALS INC
$121.36MN/A0.00%N/AN/AN/AN/A
BHC
BAUSCH HEALTH COMPANIES INC
$1.66BN/A0.00%N/AN/AN/AN/A
INDV
INDIVIOR PLC
$1.13BN/A0.00%N/AN/AN/AN/A
ETON
ETON PHARMACEUTICALS INC
$377.59MN/A0.00%N/AN/AN/AN/A
EOLS
EVOLUS INC
$642.86MN/A0.00%N/AN/AN/AN/A
PBH
PRESTIGE CONSUMER HEALTHCARE INC
$3.95BN/A0.00%$0.4750N/AN/A0
DERM
JOURNEY MEDICAL CORP
$143.48MN/A0.00%N/AN/AN/AN/A
ZTS
ZOETIS INC
$65.72B1.22%32.80%$0.5000$1.8024%02025-04-212025-06-03
NBIX
NEUROCRINE BIOSCIENCES INC
$9.98BN/A0.00%N/AN/AN/AN/A
HLN
HALEON PLC
$46.15BN/A12.20%$0.0460N/AN/A0
SNOA
SONOMA PHARMACEUTICALS INC
$3.81MN/A0.00%N/AN/AN/AN/A
LNTH
LANTHEUS HOLDINGS INC
$6.88BN/A0.00%N/AN/AN/AN/A
EBS
EMERGENT BIOSOLUTIONS INC
$251.04MN/A0.00%N/AN/AN/AN/A
TKNO
ALPHA TEKNOVA INC
$308.33MN/A0.00%N/AN/AN/AN/A
ELAN
ELANCO ANIMAL HEALTH INC
$4.01BN/A0.00%N/AN/AN/AN/A
ACB
AURORA CANNABIS INC
$238.17MN/A0.00%N/AN/AN/AN/A
SIGA
SIGA TECHNOLOGIES INC
$422.91MN/A72.30%$0.6000N/AN/A0
ASRT
ASSERTIO HOLDINGS INC
$59.48MN/A0.00%N/AN/AN/AN/A
AVDL
AVADEL PHARMACEUTICALS PLC
$787.53MN/A0.00%N/AN/AN/AN/A
ESPR
ESPERION THERAPEUTICS INC
$190.73MN/A0.00%N/AN/AN/AN/A
HROW
HARROW INC
$832.52MN/A0.00%N/AN/AN/AN/A
VTRS
VIATRIS INC
$8.82B3.25%-90.60%$0.1200$0.2462%0
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
$15.23BN/A0.00%$0.0720N/AN/A3
ALVO
ALVOTECH
$2.51BN/A0.00%N/AN/AN/AN/A
RDY
DR REDDYS LABORATORIES LTD
$11.21B0.71%24.30%$0.0958$0.1013%0
CRON
CRONOS GROUP INC
$677.08MN/AN/AN/AN/AN/AN/A
AMPH
AMPHASTAR PHARMACEUTICALS INC
$1.10BN/A0.00%N/AN/AN/AN/A
TAK
TAKEDA PHARMACEUTICAL CO LTD
$46.45BN/A144.70%$0.4064N/AN/A1
RMTI
ROCKWELL MEDICAL INC
$35.08MN/A0.00%N/AN/AN/AN/A
EVO
EVOTEC SE
$1.16BN/AN/AN/AN/AN/AN/A
OGI
ORGANIGRAM HOLDINGS INC
$131.20MN/A0.00%N/AN/AN/AN/A
KALA
KALA BIO INC
$22.39MN/A0.00%N/AN/AN/AN/A
CGC
CANOPY GROWTH CORP
$173.60MN/A0.00%N/AN/AN/AN/A
BIOA
BIOAGE LABS INC
$134.44MN/A0.00%N/AN/AN/AN/A
QNTM
QUANTUM BIOPHARMA LTD
$14.35MN/A0.00%N/AN/AN/AN/A
CRDL
CARDIOL THERAPEUTICS INC
$83.44MN/A0.00%N/AN/AN/AN/A
LFCR
LIFECORE BIOMEDICAL INC
$234.56MN/A0.00%N/AN/AN/AN/A
UPC
UNIVERSE PHARMACEUTICALS INC
$22.24kN/A0.00%N/AN/AN/AN/A
AQST
AQUESTIVE THERAPEUTICS INC
$247.18MN/A0.00%N/AN/AN/AN/A
PRFX
PAINREFORM LTD
$2.93MN/A0.00%N/AN/AN/AN/A
SCYX
SCYNEXIS INC
$35.59MN/A0.00%N/AN/AN/AN/A
RGC
REGENCELL BIOSCIENCE HOLDINGS LTD
$354.60MN/A0.00%N/AN/AN/AN/A
INCR
INTERCURE LTD
$62.43MN/A0.00%N/AN/AN/AN/A
GELS
GELTEQ LTD
$8.25MN/A0.00%N/AN/AN/AN/A
FLGC
FLORA GROWTH CORP
$9.41MN/A0.00%N/AN/AN/AN/A
CPHI
CHINA PHARMA HOLDINGS INC
$5.09MN/A0.00%N/AN/AN/AN/A
DRRX
DURECT CORP
$22.35MN/A0.00%N/AN/AN/AN/A
AYTU
AYTU BIOPHARMA INC
$6.29MN/A0.00%N/AN/AN/AN/A
BFRI
BIOFRONTERA INC
$7.41MN/A0.00%N/AN/AN/AN/A
EVOK
EVOKE PHARMA INC
$3.21MN/A0.00%N/AN/AN/AN/A
IMCC
IM CANNABIS CORP
$4.60MN/A0.00%N/AN/AN/AN/A
SXTC
CHINA SXT PHARMACEUTICALS INC
$3.86MN/A0.00%N/AN/AN/AN/A
AKAN
AKANDA CORP
$1.45MN/A0.00%N/AN/AN/AN/A
SHPH
SHUTTLE PHARMACEUTICALS HOLDINGS INC
$1.04MN/A0.00%N/AN/AN/AN/A
RDHL
REDHILL BIOPHARMA LTD
$0.00N/AN/AN/AN/AN/AN/A
CTOR
CITIUS ONCOLOGY INC
$46.22MN/A0.00%N/AN/AN/AN/A
TLPH
TALPHERA INC
$7.88MN/A0.00%N/AN/AN/AN/A
TLRY
TILRAY BRANDS INC
$479.09MN/A0.00%N/AN/AN/AN/A
YCBD
CBDMD INC
$1.35MN/A0.00%N/AN/AN/AN/A
PTPI
PETROS PHARMACEUTICALS INC
$2.14MN/A0.00%N/AN/AN/AN/A
TXMD
THERAPEUTICSMD INC
$11.46MN/A0.00%N/AN/AN/AN/A
BGM
BGM GROUP LTD
$82.24MN/A0.00%$0.2500N/AN/A0
OPTN
OPTINOSE INC
$92.26MN/A0.00%N/AN/AN/AN/A
IXHL
INCANNEX HEALTHCARE INC
$11.07MN/A0.00%N/AN/AN/AN/A
SBFM
SUNSHINE BIOPHARMA INC
$3.30MN/A0.00%N/AN/AN/AN/A

Pharmaceutical Stocks FAQ

What are the best pharmaceutical stocks to buy right now in Apr 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best pharma stocks to buy right now are:

1. Pacira Biosciences (NASDAQ:PCRX)


Pacira Biosciences (NASDAQ:PCRX) is the #1 top pharmaceutical stock out of 78 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Pacira Biosciences (NASDAQ:PCRX) is: Value: B, Growth: B, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: C.

Pacira Biosciences (NASDAQ:PCRX) has a Due Diligence Score of 23, which is -4 points lower than the pharmaceutical industry average of 27. Although this number is below the industry average, our proven quant model rates PCRX as a "A".

PCRX passed 7 out of 33 due diligence checks and has weak fundamentals. Pacira Biosciences has seen its stock lose -8.93% over the past year, overperforming other pharmaceutical stocks by 49 percentage points.

Pacira Biosciences has an average 1 year price target of $32.80, an upside of 34.04% from Pacira Biosciences's current stock price of $24.47.

Pacira Biosciences stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Pacira Biosciences, 20% have issued a Strong Buy rating, 40% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Hutchmed (NASDAQ:HCM)


Hutchmed (NASDAQ:HCM) is the #2 top pharmaceutical stock out of 78 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Hutchmed (NASDAQ:HCM) is: Value: B, Growth: A, Momentum: C, Sentiment: A, Safety: C, Financials: C, and AI: C.

Hutchmed (NASDAQ:HCM) has a Due Diligence Score of 48, which is 21 points higher than the pharmaceutical industry average of 27.

HCM passed 16 out of 33 due diligence checks and has strong fundamentals. Hutchmed has seen its stock lose -17.63% over the past year, overperforming other pharmaceutical stocks by 40 percentage points.

3. Supernus Pharmaceuticals (NASDAQ:SUPN)


Supernus Pharmaceuticals (NASDAQ:SUPN) is the #3 top pharmaceutical stock out of 78 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Supernus Pharmaceuticals (NASDAQ:SUPN) is: Value: A, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: B.

Supernus Pharmaceuticals (NASDAQ:SUPN) has a Due Diligence Score of 58, which is 31 points higher than the pharmaceutical industry average of 27.

SUPN passed 18 out of 33 due diligence checks and has strong fundamentals. Supernus Pharmaceuticals has seen its stock return 4.35% over the past year, overperforming other pharmaceutical stocks by 62 percentage points.

Supernus Pharmaceuticals has an average 1 year price target of $36.00, an upside of 17.23% from Supernus Pharmaceuticals's current stock price of $30.71.

Supernus Pharmaceuticals stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Supernus Pharmaceuticals, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the pharmaceutical stocks with highest dividends?

Out of 7 pharmaceutical stocks that have issued dividends in the past year, the 3 pharmaceutical stocks with the highest dividend yields are:

1. Siga Technologies (NASDAQ:SIGA)


Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of N/A, which is N/A percentage points lower than the pharmaceutical industry average of 2.42%.

Siga Technologies's dividend payout ratio of 72.3% indicates that its dividend yield is sustainable for the long-term.

2. Perrigo Co (NYSE:PRGO)


Perrigo Co (NYSE:PRGO) has an annual dividend yield of 3.35%, which is 1 percentage points higher than the pharmaceutical industry average of 2.42%. Perrigo Co's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Perrigo Co's dividend has shown consistent growth over the last 10 years.

Perrigo Co's dividend payout ratio of -88.6% indicates that its dividend yield might not be sustainable for the long-term.

3. Viatris (NASDAQ:VTRS)


Viatris (NASDAQ:VTRS) has an annual dividend yield of 3.25%, which is 1 percentage points higher than the pharmaceutical industry average of 2.42%. Viatris's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Viatris's dividend has shown consistent growth over the last 10 years.

Viatris's dividend payout ratio of -90.6% indicates that its dividend yield might not be sustainable for the long-term.

Why are pharmaceutical stocks down?

Pharmaceutical stocks were down -1.15% in the last day, and down -1.68% over the last week. Dynavax Technologies was the among the top losers in the drug manufacturers - specialty & generic industry, dropping -6.66% yesterday.

Shares of vaccine stocks are trading lower after CDC advisers begins a review of vaccine guidelines and discussed a more narrow use of COVID-19 booster shots.

What are the most undervalued pharmaceutical stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued pharmaceutical stocks right now are:

1. Ironwood Pharmaceuticals (NASDAQ:IRWD)


Ironwood Pharmaceuticals (NASDAQ:IRWD) is the most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 29, which is 13 points higher than the pharmaceutical industry average of 16. It passed 2 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has dropped -90.49% in the past year. It has underperformed other stocks in the pharmaceutical industry by -32 percentage points.

2. Bausch Health Companies (NYSE:BHC)


Bausch Health Companies (NYSE:BHC) is the second most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bausch Health Companies has a valuation score of 0, which is -16 points higher than the pharmaceutical industry average of 16. It passed 0 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates BHC a Valuation Rating of "A".

Bausch Health Companies's stock has dropped -48.51% in the past year. It has overperformed other stocks in the pharmaceutical industry by 10 percentage points.

3. Collegium Pharmaceutical (NASDAQ:COLL)


Collegium Pharmaceutical (NASDAQ:COLL) is the third most undervalued pharmaceutical stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Collegium Pharmaceutical has a valuation score of 57, which is 41 points higher than the pharmaceutical industry average of 16. It passed 4 out of 7 valuation due diligence checks.

Collegium Pharmaceutical's stock has dropped -23.67% in the past year. It has overperformed other stocks in the pharmaceutical industry by 34 percentage points.

Are pharmaceutical stocks a good buy now?

50% of pharmaceutical stocks rated by analysts are a strong buy right now. On average, analysts expect pharmaceutical stocks to rise by 56.4% over the next year.

11.32% of pharmaceutical stocks have a Zen Rating of A (Strong Buy), 15.09% of pharmaceutical stocks are rated B (Buy), 58.49% are rated C (Hold), 9.43% are rated D (Sell), and 5.66% are rated F (Strong Sell).

What is the average p/e ratio of the drug manufacturers - specialty & generic industry?

The average P/E ratio of the drug manufacturers - specialty & generic industry is 20.54x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.